← Back
Data updated: Mar 10, 2026
INNOGENIX
CardiovascularNeurologyOncology
INNOGENIX is a generic drug manufacturer focused on Cardiovascular, Neurology, Oncology.
1986
Since
5
Drugs
-
Trials
107
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
METRONIDAZOLE 2026-02-17
Labeling
METRONIDAZOLE 2026-02-17
Labeling
METRONIDAZOLE 2026-02-13
PROPRANOLOL HYDROCHLORIDE 2026-01-27
METOLAZONE 2026-01-07
Manufacturing (CMC)
HALOPERIDOL 2025-12-18
PILOCARPINE HYDROCHLORIDE 2025-10-02
METRONIDAZOLE 2025-07-09
PROPRANOLOL HYDROCHLORIDE 2025-05-08
Labeling
PILOCARPINE HYDROCHLORIDE 2025-04-28
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 50%
2 drugs
Neurology 25%
1 drugs
Oncology 25%
1 drugs
Pipeline Strength Pro
Loading...
Discontinued (2)
Company Info
- First Approval
- 1986-07-16
- Latest
- 2026-01-07
- Applications
- 5